A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3

FEBS Letters

Volumn 586, Issue 22, 2012, Pages 3996-4001

  Pennington, Michael W ^a   Harunur Rashid, M ^b   Tajhya, Rajeev B ^c   Beeton, Christine ^c   Kuyucak, Serdar ^b   Norton, Raymond S ^d  

^a Peptides International   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d MONASH UNIVERSITY   (Australia)

Author keywords

C terminal amide; Electrophysiology; Potassium channel; Potential of mean force; ShK; Umbrella sampling

Indexed keywords

PEPTIDE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.3; SERINYLHISTIDYLLYSINE; SERINYLHISTIDYLLYSYLLYSYLAMIDE; UNCLASSIFIED DRUG;

AMIDATION; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ALGORITHMS; AMIDES; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CNIDARIAN VENOMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ION CHANNEL GATING; KV1.1 POTASSIUM CHANNEL; KV1.3 POTASSIUM CHANNEL; MICE; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; T-LYMPHOCYTES;

ACTINIARIA;

EID: 84868588812     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2012.09.038     Document Type: Article

References (29)

1. + channel in effector memory T cells as new target for MS J. Clin. Invest. 111 2003 1703 1713
2. C. Beeton Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases Proc. Natl. Acad. Sci. USA 103 2006 17414 17419
3. C. Beeton, M.W. Pennington, and R.S. Norton Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases Inflamm. Allergy Drug Targets 10 2011 313 321
4. V. Chi Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases Toxicon 59 2012 529 546
5. O. Castaneda Characterization of a potassium channel toxin from the Caribbean Sea anemone Stichodactyla helianthus Toxicon 33 1995 603 613
6. J. Pohl, F. Hubalek, M.E. Byrnes, K.R. Nielsen, A. Woods, and M.W. Pennington Assignment of the three disulfide bonds in ShK toxin, a potent potassium channel blocker from the sea anemone Stichodactyla helianthus Lett. Pept. Sci. 1 1994 291 297
7. J.E. Tudor, P.K. Pallaghy, M.W. Pennington, and R.S. Norton Solution structure of ShK toxin, a novel potassium channel inhibitor from a sea anemone Nat. Struct. Biol. 3 1996 317 320
8. J.E. Tudor, M.W. Pennington, and R.S. Norton Ionisation behaviour and solution properties of the potassium-channel blocker ShK toxin Eur. J. Biochem. 251 1998 133 141
9. M.W. Pennington, V.M. Mahnir, I. Khaytin, I. Zaydenberg, M.E. Byrnes, and W.R. Kem An essential binding surface for ShK toxin interaction with rat brain potassium channels Biochemistry 35 1996 16407 16411
10. M.W. Pennington, V.M. Mahnir, D.S. Krafte, I. Zaydenberg, M.E. Byrnes, I. Khaytin, K. Crowley, and W.R. Kem Identification of three separate binding sites on ShK toxin, a potent inhibitor of voltage-dependent potassium channels in human T-lymphocytes and rat brain Biochem. Biophys. Res. Commun. 219 1996 696 701
11. H. Rauer, M. Pennington, M. Cahalan, and K.G. Chandy Structural conservation of the pores of calcium-activated and voltage-gated potassium channels determined by a sea anemone toxin J. Biol. Chem. 274 1999 21885 21892
12. K. Kalman ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide J. Biol. Chem. 273 1998 32697 32707
13. M.D. Lanigan, K. Kalman, Y. Lefievre, M.W. Pennington, K.G. Chandy, and R.S. Norton Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3 Biochemistry 41 2002 11963 11971
14. + channels and inhibits T lymphocyte proliferation J. Biol. Chem. 283 2008 988 997
15. C. Beeton Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases Mol. Pharmacol. 67 2005 1369 1381
16. L. Yan Stichodactyla helianthus peptide, a pharmacological tool for studying Kv3.2 channels Mol. Pharmacol. 67 2005 1513 1521
17. C. Beeton A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes J. Biol. Chem. 278 2003 9928 9937
18. M.W. Pennington Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes Mol. Pharmacol. 75 2009 762 773
19. M.H. Rashid, and S. Kuyucak Affinity and selectivity of ShK toxin for the Kv1 potassium channels from free energy simulations J. Phys. Chem. B 116 2012 4812 4822
20. P.C. Chen, and S. Kuyucak Accurate determination of the binding free energy for KcsA-charybdotoxin complex from the potential of mean force calculations with restraints Biophys. J. 100 2011 2466 2474
21. W. Humphrey, A. Dalke, and K. Schulten VMD: visual molecular dynamics J. Mol. Graph. 14 33-8 1996 27 28
22. C. Dominguez, R. Boelens, and A.M. Bonvin HADDOCK: a protein-protein docking approach based on biochemical or biophysical information J. Am. Chem. Soc. 125 2003 1731 1737
23. J.C. Phillips Scalable molecular dynamics with NAMD J. Comput. Chem. 26 2005 1781 1802
24. A.D. MacKerell, D. Bashford, R.L. Bellott, R.L.J. Dunbrack, and J.D. Evanseck All-atom empirical potential for molecular modeling and dynamics studies of proteins J. Phys. Chem. B 102 1998 3586 3616
25. A.D. MacKerell Jr.; M. Feig, and C.L. Brooks 3rd. Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations J. Comput. Chem. 25 2004 1400 1415
26. S. Kumar, D. Bouzida, R.H. Swensen, P.A. Kollman, and J.M. Rosenberg The weighted histogram analysis method for free-energy calculations on biomolecules J. Comput. Chem. 25 1992 1400 1415
27. + channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines Mol. Pharmacol. 45 1994 1227 1234
28. S.C. Chang, C.A. Galea, E.W. Leung, R.B. Tajhya, C. Beeton, M.W. Pennington, and R.S. Norton Expression and isotopic labelling of the potassium channel blocker ShK toxin as a thioredoxin fusion protein in bacteria Toxicon 60 2012 840 850
29. E.J. Tarcha Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease J. Pharmacol. Exp. Ther. 342 2012 642 653